Viventia Expands Leadership Team, Names Arthur P. DeCillis, M.D., as Chief Medical Officer
September 17, 2015 14:45 ET
|
Viventia Bio Inc.
WINNIPEG, Manitoba, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced that Arthur P. DeCillis,...
Viventia Reports on Progress of Anti-Cancer Pipeline at PEGS Korea 2015
September 04, 2015 12:10 ET
|
Viventia Bio Inc.
WINNIPEG, Manitoba and PHILADELPHIA, Sept. 4, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, announced that Gregory...
Viventia Recognizes Chairman Leslie Dan's 50 Years of Leadership in Healthcare
July 16, 2015 08:00 ET
|
Viventia Bio Inc.
WINNIPEG, Manitoba, July 16, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today recognized Leslie L. Dan, Founder...
Viventia Begins Recruitment of Clinical Centers as it Prepares to Initiate Phase 3 Clinical Trial of Vicinium(TM) for the Treatment of Non-Muscle-Invasive Bladder Cancer
July 02, 2015 12:45 ET
|
Viventia Bio Inc.
WINNIPEG, Manitoba, July 2, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced that they have begun...
Viventia Announces 2015 Additions to Its Board of Directors
June 23, 2015 08:00 ET
|
Viventia Bio Inc.
WINNIPEG, Manitoba, June 23, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced the expansion of its...
Viventia Presents Validating Evidence for Highly Differentiated De-immunized Payload for Oncology at 13th Empowered Antibodies Conference
June 17, 2015 08:00 ET
|
Viventia Bio Inc.
- Viventia's Protein Toxin DeBouganin Shows Advantages in Uniform Killing of Diverse Cancer Cell Lines, Avoidance of Multi-Drug Resistance Affecting Small Molecule Toxins, and Efficacy against...
Viventia Bio Inc. Expands Leadership Team, Names Erick Lucera as Chief Financial Officer and Gregory Adams, Ph.D., Chief Product Development Officer
June 05, 2015 08:00 ET
|
Viventia Bio Inc.
WINNIPEG, Manitoba, June 5, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced the expansion of the...